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Précis: Using a novel in vivo human experimental model, we show that hypoglycemia primes 53 
the innate immune system leading to a more profound inflammatory response to a subsequent 54 
inflammatory stimulus. 55 
 56 
Abstract  57 
Context  58 
Hypoglycemia is emerging as a risk for cardiovascular events in diabetes. We hypothesized 59 
that hypoglycemia activates the innate immune system, which is known to increase 60 
cardiovascular risk. 61 
Objective 62 
To determine whether hypoglycemia modifies subsequent innate immune system responses. 63 
Design and Setting 64 
Single-blinded, prospective study of three independent parallel groups. 65 
Participants and Interventions 66 
Twenty-four healthy participants underwent either a hyperinsulinemic-hypoglycemic (2.5 67 
mmol/l), euglycemic (6.0 mmol/l) or sham-saline clamp (n=8 for each group). Forty-eight 68 
hours later, all participants received low-dose (0.3 ng/kg) intravenous endotoxin.  69 
Main outcome measures 70 
We studied in-vivo monocyte mobilization and monocyte-platelet interactions. 71 
 72 
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Results 73 
Hypoglycemia increased total leucocytes (9.98±1.14 x109/l vs euglycemia: 4.38±0.53 x109/l; 74 
P<0.001 vs sham-saline: 4.76±0.36 x109/l; P<0.001) (mean±SEM), mobilized 75 
proinflammatory intermediate monocytes (42.20±7.52/μl vs euglycemia: 20.66±3.43/μl; 76 
P<0.01 vs sham-saline: 26.20±3.86/μl; P<0.05) and non-classical monocytes (36.16±4.66/μl 77 
vs euglycemia: 12.72±2.42/μl; P<0.001 vs sham-saline: 19.05±3.81/μl; P<0.001). Following 78 
hypoglycemia vs euglycemia, platelet aggregation to agonist (AUC) increased (73.87±7.30 vs 79 
52.50±4.04; P<0.05) and formation of monocyte-platelet aggregates increased 80 
(96.05±14.51/μl vs 49.32±6.41/μl; P<0.05). Within monocyte subsets, hypoglycemia 81 
increased aggregation of intermediate monocytes (10.51±1.42/μl vs euglycemia: 82 
4.19±1.08/μl; P<0.05 vs sham-saline: 3.81±1.42/μl; P<0.05) and non-classical monocytes 83 
(9.53±1.08/μl vs euglycemia: 2.86±0.72/μl; P<0.01 vs sham-saline: 3.08±1.01/μl; P<0.05) 84 
with platelets compared to controls. Hypoglycemia led to greater leucocyte mobilization in 85 
response to subsequent low-dose endotoxin challenge (10.96±0.97 vs euglycemia: 8.21±0.85 86 
x109/l; P<0.05). 87 
Conclusions 88 
Hypoglycemia mobilizes monocytes, increases platelet reactivity, promotes interaction 89 
between platelets and proinflammatory monocytes, and potentiates the subsequent immune 90 
response to endotoxin. These changes may contribute towards increased cardiovascular risk 91 
observed in people with diabetes. 92 
 93 
 94 
 95 
 96 
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Introduction 97 
Hypoglycemia is associated with a greater propensity to adverse cardiovascular (CV) 98 
outcomes in diabetes (1-3). To determine if such outcomes were dependent upon changes in 99 
innate immune responses, we devised a novel model whereby subjects were challenged with 100 
a hypoglycemic clamp, and then the durable effects on the innate immune system probed by 101 
an in vivo endotoxin challenge 48 hours later. 102 
 103 
Iatrogenic hypoglycemia remains a major barrier to effective treatment of insulin-treated 104 
diabetes (4). The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial showed 105 
that intensive glucose control, during which patients were exposed to significantly more 106 
hypoglycemia (5), was associated with excess CV mortality. Despite the evidence confirming 107 
an association between hypoglycemia and mortality, cause and effect has not been 108 
established. Trial evidence suggests that the relationship is, at least in part, explained by 109 
‘confounding’, i.e. that hypoglycemia identifies individuals with comorbidities who are both 110 
vulnerable to hypoglycemia and more likely to die for other reasons (6). Nevertheless, a 111 
recent large meta-analysis (7) has suggested that comorbidities alone are unlikely to explain 112 
this relationship. Furthermore, there is a growing body of evidence highlighting a number of 113 
mechanisms whereby hypoglycemia may lead to CV events (8, 9). 114 
 115 
Hypoglycemia has proinflammatory consequences, including increases in levels of factor 116 
VIII and von Willebrand factor and impaired fibrinolysis (10-12). In addition, hypoglycemia 117 
has been shown to increase proinflammatory cytokines (12-14) and promote rises in the 118 
levels of proatherogenic cell adhesion molecules (12). Repeated episodes of hypoglycemia 119 
have also been reported to impair nitric oxide-mediated vasodilation (15).  120 
 121 
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Monocytes are phagocytes that are central to the etiology of atherosclerosis (16) and play a 122 
role in precipitating acute CV events by promoting plaque destabilization and rupture (17). 123 
The extent to which monocytosis and monocyte activation is modified by hypoglycemia 124 
remains uncertain. Recent studies have also determined that monocytes can be classified into 125 
3 distinct subsets, termed classical monocytes (CM: CD14++ CD16-, ‘Mon1’), intermediate 126 
monocytes (IM: CD14++ CD16+, ‘Mon2’), and non-classical monocytes (NCM: CD14+ 127 
CD16++, ‘Mon3’) (18, 19). A number of observational studies indicate that IM may be 128 
particularly proatherogenic. Elevated levels of IM are associated with adverse CV outcomes 129 
(20-23), independently predict future CV events (22), and have been associated with coronary 130 
plaque vulnerability in patients with angina (24). Elevated levels of CM may also 131 
independently predict CV events (25).  132 
 133 
Acute myocardial infarction (AMI) results in monocytosis, mediated by sympathetic nervous 134 
system activation (26). In humans, CD16+ monocytes selectively mobilize, in a 135 
catecholamine-dependent fashion, following exercise (27). As epinephrine is the key counter-136 
regulatory hormone produced in response to hypoglycemia, we hypothesized that 137 
hypoglycemia would also exert significant effects on monocytes. We further hypothesized 138 
that we would see additional synergistic changes in monocyte and platelet activation, as 139 
revealed by formation of monocyte-platelet aggregates, which are increased after AMI (20, 140 
28). In large prospective studies, CV events did not appear to occur during the hypoglycemic 141 
episode per se but there was an increased risk of events in the weeks and months following 142 
the episode (29-31). We hypothesized, therefore, that acute hypoglycemia may prime the 143 
innate immune system, leading to a more pronounced inflammatory response to a subsequent 144 
inflammatory stimulus downstream from the initial episode of hypoglycemia. It is also 145 
relevant to note that people with diabetes experience increased incidences of acute and 146 
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chronic infections that will further activate innate immunity. To reveal if hypoglycemia 147 
modulated monocyte function in the human in vivo, we chose to combine a classical 148 
hypoglycemic stimulus with a subsequent in vivo systemic stimulus of the innate immune 149 
system. To achieve this, we combined hyperinsulinemic hypoglycemic-euglycemic and 150 
sham-saline clamps with low-dose intravenous endotoxin challenge 48 hours later in healthy 151 
participants.  Endotoxin, otherwise known as Gram-negative bacterial lipopolysaccharide, 152 
was employed as it induces a short-lived, sterile inflammation that is both safe and 153 
reproducible (32).   154 
Materials and Methods 155 
Study Design and Participants 156 
This was a single-blinded, prospective study of three independent parallel groups 157 
(hyperinsulinemic-hypoglycemia/euglycemia and sham-saline controls) conducted in a 158 
random group order at the Clinical Research Facility, Northern General Hospital, Sheffield, 159 
United Kingdom between January 2015 and April 2016. We therefore had three groups that 160 
had euglycemia with insulin, hypoglycaemia with insulin, or saline. Each then received 161 
endotoxin. Baseline values at the start of endotoxin administration were studied in all groups, 162 
providing a set of data obtained prior to endotoxin. Twenty-four healthy participants without 163 
diabetes were recruited from the University of Sheffield and Sheffield Teaching Hospitals 164 
with written informed consent in accordance with a protocol approved by Yorkshire and the 165 
Humber-Sheffield Research Ethics Committee (REC 14/YH/1264). All participants had a 166 
HbA1C < 6.5% (< 48 mmol/mol), measured using ion-exchange high-performance liquid 167 
chromatography, and none had impaired glucose tolerance based on HbA1C as judged by the 168 
American Diabetes Association criteria (33, 34). Participants were in good health as 169 
determined by a medical history, physical examination, vital signs and clinical laboratory test 170 
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results including full blood count and renal and liver function. Those with an intercurrent 171 
illness in the previous 4 weeks were excluded. Participants taking beta-blockers, QT interval-172 
prolonging agents and anticoagulant, antiplatelet or antiinflammatory medications were also 173 
excluded. Female participants were on secure contraception and also had negative urinary 174 
pregnancy tests on the morning of the clamp and endotoxin studies.  175 
 176 
Clamp studies  177 
All participants attended at 0800h after an overnight fast and were blinded to their group 178 
allocation. Participants were instructed to avoid caffeine, alcohol and vigorous exercise 24 179 
hours before the study visit. An intravenous cannula was inserted into the antecubital fossa of 180 
the non-dominant arm for insulin and dextrose infusion. A second intravenous cannula was 181 
inserted into the antecubital fossa of the dominant arm for all blood measurements except 182 
glucose. Following the application of a local anesthetic cream (EMLA, Astra-Zeneca, 183 
Macclesfield, UK) to the dorsal hand or wrist of the non-dominant arm, a retrograde cannula 184 
was inserted and the hand placed in a warming chamber (The Sheffield Hand Warmer, 185 
Sheffield, UK) at 55oC to allow arterialisation of venous blood for glucose measurement. In 186 
hypoglycemia and euglycemia study groups, a primed continuous insulin (Human Actrapid, 187 
Novo Nordisk Pharmaceuticals LT, Crawley, UK) infusion was administered at a rate of 90 188 
mU m-2 min-1 with total insulin exposure matched between groups. A 20% dextrose (Baxter, 189 
Baxter Healthcare Ltd., Thetford, UK) variable rate infusion was administered 190 
simultaneously and the rate adjusted according to arterialized whole blood glucose 191 
concentrations measured every 5 minutes using a glucose oxidase method (Yellow Springs 192 
Instrument 2300 STAT, Yellow Springs, Ohio, USA). Following a brief (30 minutes) 193 
euglycemic phase in both groups, blood glucose was lowered to 2.5 mmol/l in the 194 
hypoglycemia group and maintained for 60 minutes at this level. In the euglycemia group, 195 
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blood glucose was maintained at 6 mmol/l for 60 minutes. Participants in the sham-saline 196 
group were investigated identically but did not receive insulin/dextrose infusions and instead 197 
received a slow intravenous infusion of 0.9% sodium chloride (NaCl) (Baxter, Baxter 198 
Healthcare Ltd., Thetford, UK) at a pre-determined fixed rate. Thus, participants in the sham-199 
saline group were under normoglycemic conditions allowing us to control for the effects of 200 
insulin and dextrose. Blood was sampled at baseline and at 60 minutes. Members of staff 201 
processing assays were blinded to glucose group allocation.  202 
 203 
Endotoxin challenge 204 
Endotoxin challenge is a safe and well-studied model of innate immune activation in vivo 205 
(35). Forty-eight hours following the clamp, participants re-attended at 0800h having fasted 206 
overnight and refrained from caffeine, alcohol and vigorous exercise since the clamp visit. 207 
An intravenous cannula was inserted into the antecubital fossa of the non-dominant arm for 208 
administration of endotoxin and a second cannula inserted into the contralateral antecubital 209 
fossa for blood sampling. All participants received 0.3 ng/kg Escherichia coli O:113 210 
lipopolysaccharide (Clinical Centre Reference Endotoxin, National Institutes of Health, 211 
Bethesda, Maryland, USA). Endotoxin powder was reconstituted in 1 ml of sterile 0.9% NaCl 212 
to form a solution at a concentration of 1000 ng/ml, which was vortexed for 60 minutes. The 213 
weight-adjusted dose of endotoxin was obtained from this solution, added to 5 ml of 0.9% 214 
NaCl and administered as a slow bolus injection over 1 minute. An intravenous infusion of 215 
500 ml of 0.9% NaCl (Baxter, Baxter Healthcare Ltd., Thetford, Norfolk, UK) then continued 216 
for 4 hours following endotoxin to avoid hypotension. Venous blood was sampled at baseline 217 
and 2, 4 and 6 hours following endotoxin. All laboratory measurements were performed by 218 
staff blinded to glucose group allocation. 219 
 220 
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Biochemical analysis 221 
To measure epinephrine, venous forearm blood was collected into chilled lithium heparin 222 
tubes and centrifuged at 4oC, 1000g for 10 minutes. The resulting supernatant was stored at -223 
80oC until assayed by high-performance liquid chromatography. To determine insulin levels, 224 
EDTA-anticoagulated blood was centrifuged at 3000g for 10 minutes, and free insulin levels 225 
measured in the resulting plasma using an immunoassay (Roche Cobas, Roche Diagnostics, 226 
Burgess Hill, West Sussex, UK). Venous blood was centrifuged at 3000g for 10 minutes and 227 
the resulting serum used to measure cortisol and growth hormone using an 228 
immunoradiometric assay (Roche Cobas, Roche Diagnostics, Burgess Hill, West Sussex, 229 
UK). Sample collection for cortisol and growth hormone was controlled for time of day 230 
across the three study groups. 231 
 232 
 233 
Cell counts and flow cytometry 234 
Total and differential white blood cell (WBC) and platelet counts in EDTA-anticoagulated 235 
blood were determined using an automated clinical grade Sysmex cell counter (XN-9000, 236 
Sysmex, Milton Keynes, UK). For the clamp visit, alternative WBC counting methodologies 237 
were piloted for the first two subjects in each group but these were later deemed less accurate 238 
than the Sysmex cell counter. Data shown below in Figures 2, 3 and 4a, 4c, 4d, 4e and 4f are 239 
Sysmex data from n=6 in each study group. Flow cytometry was used to determine 240 
monocyte-platelet aggregates (MPA): blood was collected into tubes containing trisodium 241 
citrate dihydrate (3.13% w/v) and incubated in a heat block at 37oC for 10 minutes, 242 
erythrocytes lysed using fluorescence-activated cell sorting (FACS) lyse solution (BD, 243 
Oxford, UK) and stained with FITC-conjugated CD16 (BioLegend, London, UK), APC-244 
conjugated CD14 (BioLegend, London, UK) and PE-conjugated CD42a (BD, Oxford, UK) in 245 
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addition to matched isotype controls. Cells were fixed using FACS Fix (BD, Oxford, UK) 246 
and analyzed using flow cytometry (Accuri C6 multi-colour flow cytometer, BD, Oxford, 247 
UK) within a consistent time frame for all subjects. Monocytes were gated based on 248 
morphology and CD14 expression. Neutrophils were gated on morphology and through 249 
exclusion of monocytes. Monocyte-platelet aggregation was determined by measuring 250 
monocyte mean fluorescence of the platelet-specific marker CD42a. To phenotype and 251 
enumerate monocyte subsets, anticoagulated blood was stained with FITC-conjugated CD16 252 
(BioLegend, London, UK), APC-conjugated CD14 (BioLegend, London, UK), PE-253 
conjugated CD66c (BD Biosciences, Oxford, UK), PE-Cy7-conjugated CD11b (BioLegend, 254 
London, UK) and (PerCP)-eFluor® 710-conjugated CX3CR1 (eBioscience, Altrincham, 255 
UK). Matched isotype controls and a ‘fluorescence minus one’ strategy optimized 256 
compensation. Stained whole blood was lysed with FACS lyse as above, and the pellet 257 
resuspended in PBS prior to fixation using 1% w/v formaldehyde. Samples were immediately 258 
processed for analysis using flow cytometry (LSRII, BD, Oxford, UK). Monocytes were 259 
gated based on morphological characteristics and through the exclusion of neutrophils using 260 
CD66c. Monocyte subsets were identified based on relative expression of CD14 and CD16. 261 
Flow cytometry data were analysed using Flow Jo (FlowJo, version 10, Ashland, Oregon, 262 
USA). 263 
 264 
Platelet aggregation 265 
Platelet aggregation was measured using impedance aggregometry (Multiplate®, Verum 266 
Diagnostica GmBH, Munich, Germany). Aliquots of 300μl saline and 300μl hirudin-267 
anticoagulated blood were added to the cuvette and incubated at 37 oC for 3 minutes. Twenty 268 
microliters of adenosine diphosphate (ADP, at a final concentration of 6.45μM) was added as 269 
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agonist and the assay commenced. The area-under-the curve (AUC) was measured, which 270 
represents the level of platelet aggregation. 271 
Statistical analysis 272 
Our pilot data indicated that a sample size of 7 participants per group would have 90% power 273 
to detect a 50% relative difference in mobilization of monocytes between hypoglycemia and 274 
controls. Eight subjects were recruited per group to allow for a 13% drop out rate. Mean 275 
baseline measurements of glucose were compared between groups using analysis of variance 276 
(ANOVA). Mean measurements of glucose, insulin, and epinephrine at 60 minutes post 277 
clamp were compared, adjusting for clamp baseline measurement, using analysis of 278 
covariance (ANCOVA). In the event of unequal variance between groups, a log transform 279 
was applied and the analysis repeated. Longitudinal and between-group comparisons were 280 
made for post-endotoxin measurements using mixed effects linear models. For models 281 
examining between-group differences, the baseline endotoxin measurement was included as a 282 
covariate. For all mixed-effects linear models, an autoregressive correlation structure (AR1) 283 
was used to allow for the correlation between multiple measurements on the same person. 284 
Planned contrasts were made versus baseline and between groups at equivalent time points 285 
with Sidak’s correction for multiple comparisons. All data are expressed as mean ± SEM, 286 
unless otherwise specified, and a P value of < 0.05 was deemed statistically significant. 287 
Analysis was performed using SPSS (version 22.0, IBM, Chicago, Illinois, USA). 288 
Results 289 
Participants 290 
Study participants across the three groups were well matched for age, sex, BMI, HbA1C and 291 
total WBC count with no significant differences at screening (Table 1). Participant numbers 292 
at each stage of study is illustrated in a flow diagram (Supplemental flow diagram). 293 
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 294 
Clamp studies 295 
Glucose, insulin and counter regulatory hormones 296 
Arterialized blood glucose values are shown in Fig. 1a. The glucose values were 2.51 ± 0.11 297 
mmol/l and 6.04 ± 0.16 mmol/l at the end of the hypoglycemia and euglycemia clamps, 298 
respectively. Glucose values at the end of the sham-saline clamp were 4.64 ± 0.09 mmol/l. A 299 
counterregulatory response to hypoglycemia was evident with epinephrine levels during 300 
hypoglycemia (1.87 ± 0.25 nmol/l) being significantly higher (P < 0.001) compared to 301 
euglycemia (0.07 ± 0.01 nmol/l) and sham-saline (0.10 ± 0.04 nmol/l) (Fig. 1b). Free insulin 302 
levels at the end of clamp were similar between hypoglycemia (968.5 ± 149.1 pmol/l) and 303 
euglycemia groups (1025.4 ± 81.4 pmol/l, P = 0.996) but significantly higher (P < 0.001) 304 
then those in the sham-saline (31.3 ± 6.3 pmol/l) group (Fig. 1c). Serum cortisol and growth 305 
hormone were significantly higher in the hypoglycemia group compared to euglycemia and 306 
sham-saline controls (Fig. 1d and 1e). 307 
 308 
Total and differential leucocyte count 309 
We determined if hypoglycemia results in changes in circulating leucocytes. Hypoglycemia 310 
significantly increased the total number of WBC compared to controls (Fig. 2a). There was 311 
an increase across all classes of leucocytes studied, including neutrophils (Fig. 2b), 312 
lymphocytes (Fig. 2c) and total monocytes (Fig. 3a).  313 
 314 
Monocyte subsets 315 
We sought to determine if hypoglycemia exerted specific effects on monocyte subsets 316 
associated with cardiac pathology. Hypoglycemia increased the absolute number of all three 317 
circulating monocyte subsets compared to euglycemia and sham-saline (Fig. 3b-d). The 318 
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number of circulating NCM after 60 minutes of hypoglycemia compared to baseline (17.6 ± 319 
2.9 cells/μl) increased twofold. IM numbers after 60 minutes of hypoglycemia compared to 320 
baseline (23.2 ± 4.5 cells/μl) increased by a factor of 1.81 and CM after 60 minutes of 321 
hypoglycemia compared to baseline (442.4 ± 55.3 cells/μl) increased by a factor of 1.29. 322 
There were no significant differences in the baseline values of all three monocyte subsets 323 
between the study groups. 324 
 325 
Platelet count, aggregation and monocyte-platelet aggregates 326 
Activation of platelets and generation of platelet-leucocyte aggregates contribute to leucocyte 327 
mobilization and inflammation in the vasculature (36). We therefore studied platelet number 328 
and function and their interaction with leucocytes. Total platelet count increased in 329 
hypoglycemia compared to euglycemia and sham-saline controls (Fig. 4a). ADP-induced 330 
platelet aggregation increased following 60 minutes of hypoglycemia versus euglycemia (P = 331 
0.014) and there was numerically, but not statistically significantly, higher platelet 332 
aggregation detected in the hypoglycemia group compared to sham-saline group (P = 0.064) 333 
(Fig. 4b). The total number of MPA increased following 60 minutes of hypoglycemia 334 
compared to euglycemia (Fig. 4c). Whilst total MPA were not significantly higher in 335 
hypoglycemia compared to sham-saline controls at 60 minutes (Fig. 4c), we observed specific 336 
increases in non-classical monocyte (NCM) and intermediate monocyte (IM)-platelet 337 
aggregates (Fig. 4d and 4e). Classical monocyte (CM)-platelet aggregates appeared to 338 
increase following 60 minutes of hypoglycemia versus euglycemia and sham-saline but this 339 
was not statistically significant (P = 0.054) (Fig. 4f). 340 
 341 
 342 
 343 
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 344 
Cell surface markers 345 
To further explore the activation state of monocytes after hypoglycemia, we studied 346 
expression levels of chemokine receptor CX3CR1 and integrin CD11b. Hypoglycemia did not 347 
alter the expression of CX3CR1 or CD11b (Supplemental Fig. 1a and 1b).  348 
 349 
Endotoxin challenge 350 
To determine if prior hypoglycemia affected the subsequent response to a classical immune 351 
activator, and thus to reveal if hypoglycemia had any longer-lasting effects on the innate 352 
immune system, we next proceeded to a low-dose intravenous endotoxin challenge 48 hours 353 
after the hypoglycemic challenge in all subjects. Consistent with the low-dose model 354 
employed, no fever or significant change in mean arterial blood pressure was recorded 355 
following endotoxin challenge across the study groups. 356 
 357 
Epinephrine, cortisol and growth hormone 358 
In contrast to the stress response induced by hypoglycemia, epinephrine levels were not 359 
significantly different between study groups 6 hours following endotoxin administration (Fig. 360 
5a). In the hypoglycemia group, epinephrine levels were 0.15 ± 0.04 nmol/l versus 0.06 ± 361 
0.01 nmol/l in euglycemia group and 0.09 ± 0.01 nmol/l in sham-saline group. There were 362 
also no differences detected between groups in serum cortisol and growth hormone levels 363 
following endotoxin administration (Fig. 5b and 5c). However, a rise versus baseline in the 364 
stress hormone cortisol was evident whereby serum cortisol levels peaked at 4 hours 365 
following endotoxin challenge in all study groups (P = 0.005) (Fig. 5b). 366 
 367 
 368 
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 369 
Total and differential leucocyte count 370 
We observed that antecedent hypoglycemia modulated the subsequent WBC response to 371 
endotoxin. Total number of WBC increased significantly following endotoxin in all the study 372 
groups (Fig. 6a). The peak WBC response occurred at 4 hours post endotoxin and this was 373 
significantly higher in the hypoglycemia group at 10.96 ± 0.97x109/l vs 8.21 ± 0.85x109/l in 374 
the euglycemia group (P = 0.012) (Fig. 6a). Total WBC count 4 hours post endotoxin in the 375 
sham-saline group was 10.65 ± 0.64x109/l and this was significantly higher compared to 376 
euglycemia (P = 0.033), but not hypoglycemia (P = 0.974). The rise in WBC was mainly a 377 
consequence of an increase in neutrophil count (Fig. 6b). The lymphocyte count decreased 378 
following endotoxin (Fig. 6c) and the monocyte count initially decreased prior to recovery 6 379 
hours post endotoxin (Fig. 7a). There was a trend towards a higher total monocyte count in 380 
the hypoglycemia group 4 hours post endotoxin compared to euglycemia but this comparison 381 
did not reach statistical significance (P = 0.085). The absolute number of circulating 382 
monocyte subsets did not differ significantly between study groups (Fig. 7b, 7c and 7d). 383 
NCM and IM numbers decreased significantly following endotoxin compared to baseline 384 
values in all groups (P < 0.001) (Fig. 7b and 7c). Compared to baseline, CM numbers 385 
significantly declined at 2 hours (P < 0.001), prior to rising and reaching a peak at 6 hours (P 386 
< 0.001) (Fig. 7d). 387 
 388 
Cell surface markers 389 
We examined monocyte activation following endotoxin exposure by measurement of cell 390 
surface marker CX3CR1 expression. Endotoxin administration caused a significant decline in 391 
expression of this marker across all study groups compared to baseline (P < 0.001) 392 
(Supplemental Fig. 2a). This was accompanied by an increase in the concentration of 393 
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CX3CL1 in plasma at 4 and 6 hours compared to baseline in all groups (P < 0.001) 394 
(Supplemental Fig. 2e). Activation of monocytes was also revealed by increased expression 395 
of CD11b expression at 4 and 6 hours following endotoxin compared to baseline in all groups 396 
(P < 0.001) (Supplemental Fig. 3a). In addition, the percentage of total monocytes that were 397 
positive for CD11b expression was higher in hypoglycemia group versus euglycemia group at 398 
2 hours post endotoxin (P = 0.007) (Supplemental Fig. 3b).  399 
Discussion 400 
Hypoglycemia may contribute to exacerbations of ischemic CV disease. We aimed to 401 
investigate the effect of acute experimental hypoglycemia and subsequent low-dose 402 
endotoxemia on aspects of the innate immune response (total leucocytes, leucocyte subsets 403 
and specifically monocyte subsets), thrombosis (platelet aggregation) and cross-talk between 404 
inflammation and thrombosis (monocyte-platelet aggregates). Our main findings were: (1) 405 
hypoglycemia increased the number of all three circulating monocyte subsets, in association 406 
with a stress response characterized by increased plasma epinephrine levels; (2) 407 
hypoglycemia increased platelet reactivity, promoted formation of MPAs and promoted 408 
aggregate formation between proinflammatory monocytes and platelets; (3) leucocyte 409 
mobilization to the stress response of low-dose endotoxin was independent of epinephrine, 410 
and antecedent hypoglycemia resulted in a significantly higher inflammatory leucocyte 411 
response to low-dose endotoxin administered 48 hours later. 412 
 413 
As shown previously (13, 37), we confirm that hypoglycemia results in leucocytosis. In 414 
addition, we present, for the first time, the effect of hypoglycemia on monocyte subset 415 
kinetics and demonstrate an increase in the absolute number of all three circulating monocyte 416 
subsets. The largest increase was observed in numbers of circulating NCM (2-fold) and IM 417 
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(1.8-fold) with a modest increase in the number of CM (1.3-fold). These data are in keeping 418 
with an observed selective mobilization of CD16+ monocytes in response to exercise (27, 38) 419 
and epinephrine infusion (39). Ratter et al. also recently determined that hypoglycemia might 420 
modify selective monocyte mobilization (37). However, they did not phenotype monocyte 421 
subsets but rather measured total levels of CD16 on peripheral blood mononuclear cells 422 
isolated from both healthy participants and those with type 1 diabetes in experimental 423 
hypoglycemia settings. Our data identify specific changes in monocyte subsets that have been 424 
previously linked to monocyte activation and atherogenesis. As observational data support 425 
the notion of CD16+ monocytes being proatherogenic (20, 22-24), and adrenergic modulation 426 
of monocytes induces proinflammatory changes (40), an increase in the circulating number of 427 
these cells following hypoglycemia may enhance CV risk in diabetes. 428 
 429 
Previous studies investigating effects of hypoglycemia on platelet biology have suggested an 430 
increase in platelet reactivity; however, this was in the context of significant hypoglycemic 431 
stimulus as part of an insulin stress test (41). An older investigation into the effect of 432 
hypoglycemia on monocyte-platelet interactions in type 1 diabetes and healthy controls has 433 
also suggested a trend towards increased MPA formation, but these data were not conclusive 434 
with little difference between euglycemic and hypoglycemic conditions (42). Our study also 435 
recapitulates and extends previous findings that hypoglycemia is prothrombotic, as evidenced 436 
by an increased platelet count and increased platelet reactivity to ADP (43). We have now 437 
conclusively demonstrated an overall increase in formation of MPA in hypoglycemia in 438 
comparison to euglycemia. Furthermore, we provide novel data demonstrating MPA 439 
formation within monocyte subsets in experimental hypoglycemia. MPA formation is a 440 
highly sensitive marker of both monocyte and platelet activation (44, 45). MPA formation 441 
promotes monocyte release of the proinflammatory cytokines; TNFα, CXCL8 and CCL2 (46, 442 
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47) and increases adhesive properties of monocytes (48), thereby representing a bridge 443 
between inflammation and thrombosis, that may serve to increase CV risk. In acute coronary 444 
syndromes, MPA formation correlates with troponin elevation, risk of in-hospital cardiac 445 
events including death and risk of future cardiac events (20, 49). We have also shown that 446 
NCM and IM aggregate more readily with platelets in response to hypoglycemia compared to 447 
CM. A similar observation of proportionally higher IM-MPA and NCM-MPA formation has 448 
been reported in patients following an ST-elevation myocardial infarction (STEMI) with 449 
higher IM-MPAs in particular being a poor prognostic indicator at 6 weeks following STEMI 450 
(20). Thus, our data suggest that hypoglycemia not only increased circulating numbers of 451 
CD16+ monocytes, but also promoted increased interaction between these proinflammatory 452 
monocyte subsets and platelets.  453 
 454 
In a first model of its type, we wished to determine whether antecedent hypoglycemia 455 
modulated responses to low-dose endotoxin. We chose a low-dose endotoxin model firstly 456 
because we felt it the safest way to combine the clamp and endotoxin human models, 457 
secondly because future extension to the study of people with diabetes would be more 458 
feasible with this model, and finally because people with diabetes are often exposed to 459 
chronic low-grade infections through foot ulceration and periodontitis which might further 460 
increase the risk of CV mortality (50, 51). In our model, we observed in all groups that 461 
monocytes were activated even in response to low-dose endotoxin, as indicated by 462 
upregulation of systemic levels of the CX3CR1 ligand CX3CL1, and the upregulation of the 463 
adhesion molecule CD11b on the monocytes themselves. Interestingly, compared to 464 
euglycemia, hypoglycemia resulted in greater leucocyte mobilization in response to low-dose 465 
intravenous endotoxemia 48 hours later. Furthermore, we noted a non-significant trend 466 
towards a higher total monocyte count in the hypoglycemia group 4 hours post endotoxin 467 
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compared to euglycemia. The percentage of monocytes that were CD11b positive was also 468 
higher in hypoglycemia group compared to euglycemia group at 2 hours post endotoxin. 469 
Levels of leucocyte mobilization were similar between groups who received prior sham-470 
saline or hypoglycemia. These data suggest that euglycemia with insulin suppressed 471 
leucocyte mobilization in response to endotoxin 48 hours later, consistent with the known 472 
antiinflammatory actions of insulin (52, 53) and that the physiological stress of hypoglycemia 473 
overcame this insulin-mediated suppression of inflammatory responses. Our data show that 474 
drivers for differential leucocyte mobilization to endotoxin are unlikely to be due to 475 
differences between groups in epinephrine, cortisol and growth hormone levels post 476 
endotoxin as these were not significantly different. Our observation that a single episode of 477 
hypoglycemia compared to euglycemia invokes a stronger proinflammatory response to 478 
endotoxin up to 2 days later is of potential clinical relevance given that trial data suggest 479 
downstream mortality following hypoglycemia (29-31). 480 
 481 
The strengths of our study include use of a novel human experimental model and detailed 482 
flow cytometric analysis that allowed us to comprehensively describe immune cell kinetics 483 
and activation status in response to experimental hypoglycemia and endotoxin challenge in 484 
vivo. The separation of clamp and endotoxin studies by 48 hours allowed us to probe the 485 
longitudinal effects of hypoglycemia on innate immunity. Moreover, by using a sham-saline 486 
group, we specifically controlled for the immunological effects of insulin, thereby robustly 487 
investigating proinflammatory changes in response to hypoglycemia.  488 
 489 
One limitation was our decision to study a relatively small number of young healthy 490 
participants. This limits the applicability of our findings to older patients with diabetes, 491 
established CV risk factors and atherosclerosis. For ethical and safety reasons, we decided to 492 
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examine our novel experimental model initially in healthy participants. We also specifically 493 
adopted a low-dose endotoxin model with future translatability in older, higher-risk 494 
participants in mind. Future studies should therefore confirm our findings in those with 495 
diabetes. In addition, it is worth noting that we studied cell numbers, phenotypic changes and 496 
activation status in circulating immune cells and this may not necessarily reflect the 497 
functional capacity of these cells in an atherosclerotic plaque. An animal model of combined 498 
experimental hypoglycemia and atherosclerosis may help to resolve these questions. 499 
 500 
In conclusion, hypoglycemia mobilized proatherogenic monocyte subsets and induced 501 
prothrombotic changes by increasing platelet reactivity. In addition, hypoglycemia amplified 502 
interactions between platelets and monocytes by promoting MPA formation with enhanced 503 
aggregation of proinflammatory monocytes with platelets. Hypoglycemia may also prime the 504 
innate immune system to respond more robustly to stimuli such as endotoxin. This implies 505 
proinflammatory consequences of hypoglycemia beyond the acute episode. These data 506 
provide novel mechanistic insights into how hypoglycemia could increase CV risk through 507 
upregulation of inflammatory responses. 508 
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Table & Figure legends 695 
Table 1: Comparison of participant characteristics at baseline. Data are mean ± SD or 696 
median (interquartile range). P values indicate comparisons between study groups via  697 
parametric or nonparametric testing. BMI, body mass index; WBC, white blood cells. 698 
 699 
Figure 1: Glucose, insulin and counter-regulatory hormones in clamp studies. Arterialized 700 
whole blood glucose values during hyperinsulinemic hypoglycemic, euglycemic and sham-701 
saline clamps (a), epinephrine (b), free insulin (c), cortisol (d) and growth hormone values (e) 702 
after 60 minutes of hypoglycemia, euglycemia or sham-saline injection. Data are mean 703 
(SEM), *P<0.05, **P<0.01, ***P<0.001, ns-non-significant, P-values are provided for 704 
comparison between study groups. Black circles (and dashed line 1a)-hypoglycemia group; 705 
open circles-euglycemia group; black triangles (and solid line 1a)-sham-saline group. 706 
 707 
Figure 2: Peripheral total white blood cell, neutrophil and lymphocyte kinetics in 708 
experimental hypoglycemia and controls. Number of circulating total WBCs (a), 709 
neutrophils (b) and lymphocytes (c) after 60 minutes of hypoglycemia, euglycemia or sham-710 
saline injection. Data are mean (SEM), **P<0.01, ***P<0.001, P-values are provided for 711 
comparison between study groups. Black circles-hypoglycemia group; open circles-712 
euglycemia group; black triangles-sham-saline group. WBC, white blood cells. 713 
 714 
Figure 3: Total monocyte count and monocyte subset kinetics in experimental 715 
hypoglycemia and controls. Absolute circulating numbers of total monocytes (a) and 716 
monocyte subsets comprising of NCM (b), IM (c) and CM (d) after 60 minutes of 717 
hypoglycemia, euglycemia or sham-saline injection. Data are mean (SEM), *P<0.05, 718 
**P<0.01, ***P<0.001, P-values are provided for comparison between study groups. Black 719 
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circles-hypoglycemia group; open circles-euglycemia group; black triangles-sham-saline 720 
group. NCM, non-classical monocytes; IM, intermediate monocytes; CM, classical 721 
monocytes. 722 
 723 
Figure 4: Platelet reactivity and monocyte-platelet aggregate formation in experimental 724 
hypoglycemia and controls. Total platelet count (a), platelet aggregation to ADP 6.45 μM 725 
(b), total MPA formation (c) and MPA formation within monocyte subsets; NCM-MPA (d), 726 
IM-MPA (e) and CM-MPA (f) after 60 minutes of hypoglycemia, euglycemia or sham-saline 727 
injection. Data are mean (SEM), *P<0.05, **P<0.01, ns-non-significant, P-values are 728 
provided for comparison between study groups. Black circles-hypoglycemia group; open 729 
circles-euglycemia group; black triangles-sham-saline group. MPA, monocyte-platelet 730 
aggregates; NCM-MPA, non-classical monocyte-platelet aggregates; IM-MPA, intermediate 731 
monocyte-platelet aggregates; CM-MPA, classical monocyte-platelet aggregates.  732 
 733 
Figure 5: Changes in epinephrine, cortisol and growth hormone response post 734 
endotoxin challenge. Epinephrine (a), cortisol (b) and growth hormone (c) responses 2, 4 735 
and 6 hours following low dose (0.3 ng/kg) intravenous endotoxin challenge in participants 736 
that underwent hypoglycemia, euglycemia or a sham-saline clamp 48 hours earlier. Data are 737 
mean (SEM), **P<0.01, ns-non-significant, P-value on dashed line in (b) represents change 738 
in cortisol at 4 hours compared to baseline in all groups, solid horizontal lines represent 739 
significance for comparison between study groups. Dashed line in (a) illustrates the mean 740 
epinephrine response in hypoglycemia clamp subjects. Black circles-hypoglycemia group; 741 
open circles-euglycemia group; black triangles-sham-saline group.  742 
 743 
28 
 
Figure 6: Peripheral total white blood cell, neutrophil and lymphocyte kinetics post 744 
endotoxin challenge. Number of circulating total WBCs (a), neutrophils (b) and 745 
lymphocytes (c) 2, 4 and 6 hours following low dose (0.3 ng/kg) intravenous endotoxin 746 
challenge in participants that underwent hypoglycemia, euglycemia or a sham-saline clamp 747 
48 hours earlier. Data are mean (SEM), *P<0.05, ns-non-significant, P-values are provided 748 
for comparison between study groups, solid horizontal line in (c) represents significance for 749 
comparison between study groups. Black circles-hypoglycemia group; open circles-750 
euglycemia group; black triangles-sham-saline group. 751 
 752 
Figure 7: Total monocyte count and monocyte subset kinetics post endotoxin challenge. 753 
Absolute circulating numbers of total monocytes (a) and monocyte subsets comprising of 754 
NCM (b), IM (c) and CM (d) 2, 4 and 6 hours following low dose (0.3 ng/kg) intravenous 755 
endotoxin challenge in participants that underwent hypoglycemia, euglycemia or a sham-756 
saline clamp 48 hours earlier. Data are mean (SEM), ***P<0.001, ns-non-significant, P-value 757 
on dashed line in (b) represents change in number of NCMs at 2, 4 and 6 hours compared to 758 
baseline in all study groups. P-value on dashed line in (c) represents change in number of IM 759 
at 2, 4 and 6 hours compared to baseline in all study groups. P-value on dashed lines in (d) 760 
represent change in number of CM at 2 and 6 hours compared to baseline in all study groups. 761 
Solid horizontal lines represent significance for comparison between study groups. Black 762 
circles-hypoglycemia group; open circles-euglycemia group; black triangles-sham-saline 763 
group. NCM, non-classical monocytes; IM, intermediate monocytes; CM, classical 764 
monocytes. 765 
 766 
 767 
 768 
 769 
 770 
  771 
       
Parameter Hypoglycemia Euglycemia Sham-saline p 
Total n=24 8 8 8 N/A 
Sex (M/F) 4/4 4/4 4/4 N/A 
Age (years) 21 (19-22) 21 (20-23) 21.5 (21-26) 0.299 
BMI (kg/m2) 24 ± 2 23 ± 2 24 ± 4 0.638 
HbA1c 
% 
mmol/mol 
 
5.2 ± 0.31 
34 ± 3.6 
 
5.2 ± 0.26 
33.5 ± 2.8 
 
5.1 ± 0.14 
32.6 ± 1.4 
 
0.792 
0.616 
Total WBC  
(x109/l) 
6.26 ± 1.42 4.83 ± 0.91 4.50 ± 1.69 0.102 
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